2022
DOI: 10.1016/j.ejca.2022.02.013
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
19
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(20 citation statements)
references
References 33 publications
1
19
0
Order By: Relevance
“…However, this is less clear for further lines of treatment, with one trial suggesting a slightly longer PFS for second-line chemotherapy, although with the strong bias of a retrospective descriptive analysis only ( 19 ). Regarding the effect of FGFR target therapies on OS, two trials confirmed the positive prognostic role of FGFR alterations on their subset of patients, even after censoring those who had received targeted drugs ( 16 , 17 ), thus suggesting that the prognostic role of these molecular changes could be independent to the administered targeted treatments. On the other hand, one trial suggested the opposite ( 18 ), ascribing the OS gain to anti-FGFR therapies, although it did not provide OS for FGFR patients who had not received target therapies, making it impossible to draw definitive conclusions.…”
Section: Discussionmentioning
confidence: 96%
See 2 more Smart Citations
“…However, this is less clear for further lines of treatment, with one trial suggesting a slightly longer PFS for second-line chemotherapy, although with the strong bias of a retrospective descriptive analysis only ( 19 ). Regarding the effect of FGFR target therapies on OS, two trials confirmed the positive prognostic role of FGFR alterations on their subset of patients, even after censoring those who had received targeted drugs ( 16 , 17 ), thus suggesting that the prognostic role of these molecular changes could be independent to the administered targeted treatments. On the other hand, one trial suggested the opposite ( 18 ), ascribing the OS gain to anti-FGFR therapies, although it did not provide OS for FGFR patients who had not received target therapies, making it impossible to draw definitive conclusions.…”
Section: Discussionmentioning
confidence: 96%
“…A recent work by Rizzato et al. claimed at the multivariate model a correlation between mIDH1/2 and improved survival in a population of iCCA patients ( 17 ), reporting a median OS of 25.9 months compared to 16.3 months in wild-type patients (p = 0.06). In this paper, the benefit appears independent from targeted therapy administration, since no mutated IDH1/2 patients had received IDH1 inhibitors.…”
Section: Fibroblast Growth Factor Receptor 2 (Fgfr2)mentioning
confidence: 99%
See 1 more Smart Citation
“…30 FGFR GAs occur in approximately 10% to 16% of patients with iCCA. In retrospective studies, patients with FGFR GAs may have better prognosis than those without FGFR GAs, 31 but these studies had notable biases and require further prospective validation. 32 With the recognition that multiple solid cancers including iCCA have FGFR GAs, a series of clinical trials have shown promising response rates and durable control of oral medications that target various FGFR GAs.…”
Section: Fibroblast Growth Factor Receptormentioning
confidence: 99%
“…FGFR GAs occur in approximately 10% to 16% of patients with iCCA. In retrospective studies, patients with FGFR GAs may have better prognosis than those without FGFR GAs, 31 but these studies had notable biases and require further prospective validation 32…”
Section: Targeted Agents and Radiation For Iccamentioning
confidence: 99%